Treatment of primary cardiac diffuse large B-cell lymphoma involving the coronary sinus with R-EPOCH: a case report and literature review

Aryan Rezvani, Shilpan Shah

Research output: Contribution to journalArticlepeer-review

1 Scopus citations

Abstract

Primary cardiac lymphomas (PCLs) are a rare clinical entity, in which treatment guidelines remain to be established. Rituximab, etoposide, prednisone, vincristine, cyclophosphamide, and doxorubicin (R-EPOCH) has been proposed, given that it involves a continuous infusion of anthracycline, reducing the risk of a cardiotoxicity and therefore the theoretical risk of perforation. However, the literature on this method of treatment is scarce. Herein, we present a unique case of a 75-year-old male, diagnosed with primary cardiac diffuse large B-cell lymphoma (DLBCL) with relatively unusual involvement of the coronary sinus, treated first with one cycle of R-EPOCH, followed by three cycles of rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP) to reduce said risk. To our knowledge, this is one of two cases, in which a patient with PCL was treated this way.

Original languageEnglish (US)
Pages (from-to)2557-2560
Number of pages4
JournalAnnals of Hematology
Volume103
Issue number7
DOIs
StatePublished - Jul 2024

Keywords

  • Cardiotoxicity
  • DLBCL
  • Myocardial rupture
  • PCL
  • R-EPOCH

ASJC Scopus subject areas

  • Hematology

Cite this